2023
Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals
McNamara B, Chang Y, Goreshnik A, Santin A. Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals. International Journal Of Women's Health 2023, 15: 1353-1365. PMID: 37663226, PMCID: PMC10474218, DOI: 10.2147/ijwh.s400537.Peer-Reviewed Original ResearchAntibody-drug conjugatesReceptor-targeting antibodiesOngoing clinical trialsDrug conjugatesRelevant preclinical studiesRecent FDA approvalAnti-cancer therapyGynecologic malignanciesCytotoxic therapyGynecological cancerADC therapyClinical trialsPreclinical studiesFDA approvalTumor cellsTherapyHealthy tissueModern appraisalDeliveryMalignancyCancerConjugatesTrialsAntibodies
2018
280TiP GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer
Tewari K, Vergote I, Oaknin A, Alvarez E, Gaillard S, Lheureux S, Rischin D, Santin A, Feng M, Mathias M, Fury M, Lowy I, Monk B. 280TiP GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer. Annals Of Oncology 2018, 29: ix86. DOI: 10.1093/annonc/mdy436.027.Peer-Reviewed Original ResearchGOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer.
Tewari K, Vergote I, Oaknin A, Alvarez E, Chase D, Gaillard S, Lheureux S, Rischin D, Santin A, Feng M, Mathias M, Fury M, Lowy I, Monk B. GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer. Journal Of Clinical Oncology 2018, 36: tps5600-tps5600. DOI: 10.1200/jco.2018.36.15_suppl.tps5600.Peer-Reviewed Original Research
2017
Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials
MacKay HJ, Levine DA, Bae-Jump VL, Bell DW, McAlpine JN, Santin A, Fleming GF, Mutch DG, Nephew KP, Wentzensen N, Goodfellow PJ, Dorigo O, Nijman HW, Broaddus R, Kohn EC. Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget 2017, 5: 84579-84594. PMID: 29137450, PMCID: PMC5663622, DOI: 10.18632/oncotarget.19961.Peer-Reviewed Original ResearchEndometrial cancerClinical trialsEndometrial cancer managementEndometrial cancer trialsFuture clinical trialsActionable therapeutic targetsNCI clinical trialsNational Cancer InstituteHistologic stratificationCancer trialsCancer managementCancer InstituteMortality rateTherapeutic targetTherapeutic directionsNew drugsCancerMolecular pathwaysTrialsMeeting reportSteering CommitteeActionable opportunitiesGroup of expertsKey genesIncidence
2011
Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or nonsquamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
Santin A, Patricia G, Sill M, McMeekin D, Leitao M, Brown J, Sutton G, Van Le L, Boardman C. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or nonsquamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecologic Oncology 2011, 120: s18. DOI: 10.1016/j.ygyno.2010.12.047.Peer-Reviewed Original ResearchA phase I clinical trial of the mTOR inhibitor everolimus in combination with oral topotecan for patients with recurrent and advanced endometrial cancer
Abu-Khalaf M, Santin A, Ratner E, Silasi D, ElSahwi K, Baker L, Luther M, Azodi M, Rutherford T, Schwartz P. A phase I clinical trial of the mTOR inhibitor everolimus in combination with oral topotecan for patients with recurrent and advanced endometrial cancer. Gynecologic Oncology 2011, 120: s97-s98. DOI: 10.1016/j.ygyno.2010.12.232.Peer-Reviewed Original Research
2010
Letter to the Editor referring to the manuscript entitled: “Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study” recently reported by Fleming et al., (Gynecol Oncol., 116;15–20;2010)
Santin AD. Letter to the Editor referring to the manuscript entitled: “Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study” recently reported by Fleming et al., (Gynecol Oncol., 116;15–20;2010). Gynecologic Oncology 2010, 118: 95-96. PMID: 20172595, DOI: 10.1016/j.ygyno.2010.01.043.Peer-Reviewed Original Research